Studies testing gefitinib with TMI-002 (a compound that specifically inhibits ADAM-17 in breast cancer cell lines), did not see any additional benefit when the two agents were administered simultaneously; gefitinib treatment administered 72 hours after the ADAM inhibitor, however, was more effective, though the difference did not reach statistical significance.
1
—
—